Thymulin reduced age-associated inflammatory myeloid cells and slowed breast-tumor growth in aged mice by suppressing NF-κB signaling. The peptide also restored anti-PD-L1 responsiveness in aged mouse models, while human cell and tumor data supported an age-linked inflammatory myeloid profile.